Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047083 · ClinicalTrials.gov registry record
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 1,027
- Enrollment target
NCT03047083 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,027 participants.
The verdict
NCT03047083 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 1,027 participants
- Enrollment target
Study Summary
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
Interventions
- OTHER Treatment patterns among AML patients
- OTHER AML-related healthcare resources
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2014-06-02 |
| Est. Completion | 2016-03-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03047083
The ClinicalTrials.gov registry entry for NCT03047083 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,027 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment patterns among AML patients is the first listed.
NCT03047083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03047083 about?
NCT03047083 is a clinical study titled "Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review". The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
What is the current status of trial NCT03047083?
This trial is currently completed. The enrollment target is 1,027 participants. The study started on 2014-06-02. Estimated completion is 2016-03-18.
What interventions are being tested in trial NCT03047083?
The interventions under investigation include: Treatment patterns among AML patients (OTHER), AML-related healthcare resources (OTHER).
Who is sponsoring clinical trial NCT03047083?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.